PHARMA INDUSTRIES

INTRODUCTION
PHARMA INDUSTRIES
• India's pharm market currently stands ninth in the world market for pharmaceuticals with
a 1.5% share.
• This market is expected to reach $6 billion by 2001 and should more than double to
$19.3 billion in 2012.
• The industry's heart disease sector is expected to grow from $90 million now to more
than $560 million in 2010.
• India's pharmaceutical industry is one of the most highly regulated industries in the
country.
• Current demand in the Indian pharmaceutical sector stands at about $4 to $5 billion .
PHARMA INDUSTRIES
 KEY PRODUCTS
Poultry Medicines.
 Galenic preparations
 Probiotic complexes
 Ketorolac Tromethamine
 Bioactive Food Additives
 Ginseng+Vitamins
 Cardio vascular medicines

Physical forms: tablets, capsules, ointments and

solutions
KEY PLAYERS

Ranbaxy Laboratories Limited.

Dr. Reddy's Laboratories.


Cipla Indian pharmaceutical company
(FIRST TIME PROVIED LOW PRICE AIDS
MEDICINE)


Nicholas Piramal
CONT.

• Glaxo Smithkline (GSK )

H1N1 vaccine (NOV, 2009)

• Zydus Cadila
CONTRIBUTION TO THE ECONOMY IN TERMS OF
GDP
CONTRIBUTION TO THE ECONOMY
IN TERMS OF GDP
• The pharma industry generally grows at about 1.5-1.6 times the Gross Domestic Product
growth Globally.
• The Indian pharmaceutical industry is expected to grow at a rate of 9.9 % till 2010 and
after that 9.5 % till 2015.
• The Indian vaccine market which was worth US$665 million in 2007-08 is growing at a
rate of more than 20%.
• Direct investment to the tune of US$ 1.43 billion from April 2000 to December 2008 .
SWOT ANALYSIS
• Strengths
 Cost effective technology
 well-development manufacturing base
 High-quality formulations and drugs
 High standards of purity
 Chemical and process development competencies
 World-class process development labs
WEAKNESSES
 Low R&D investments.
 Low Indian share in world pharmaceutical market
(about 2%).
 Lack of strategic planning.
 Absence of association between institutes and Low
industry.
 Healthcare expenditure.
 Production of duplicate drugs.
OPPORTUNITIES
 Increasing health consciousness.
 New innovative therapeutic products.
 Globalization.
 Production of generic drugs.
 Contract manufacturing.
 Drug molecules.
THREATS
 Small number of discoveries
 Competition from MNCs
 Transformation of process patent to product patent (TRIPS)
 Outdated Sales and marketing methods
 Non-tariff barriers imposed by developed countries
FUTURE OF THE SECTOR
 New drug chemistries to innovative R&D partnerships.
 Marketing plans-are reshaping the business strategies of many pharmaceutical and
biotechnology companies.
 Increase productivity, decrease costs, and develop new treatment modalities that will
enhance profitability.
 R&D
 New technology.
THANK YOU